Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

🇨🇳 Laotian Times (CN) —

AI Summary

Mabwell's antibody drug 9MW5211 for inflammatory bowel disease has received clinical trial clearance from China's National Medical Products Administration, marking a significant advancement in biopharmaceutical innovation.

SHANGHAI, June 5, 2026 /PRNewswire/ — Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for inflammatory bowel disease (IBD). 9MW5211 is the first candidate drug for its target […]

World Markets Health Mabwell clinical trials inflammatory bowel disease NMPA biopharmaceuticals drug approval

Read original source →